VG Life Sciences Inc.
VGLS
$0.00
$0.000.00%
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.89% | -37.83% | -48.25% | -61.11% | -17.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.33% | -35.81% | -51.47% | -74.63% | -6.42% |
| Operating Income | 19.33% | 35.81% | 51.47% | 74.63% | 6.42% |
| Income Before Tax | 4.65% | 29.88% | 45.77% | 86.05% | 31.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.65% | 29.88% | 45.77% | 86.05% | 31.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00% | 0.00% | 0.00% | -69.06% | -7.53% |
| Net Income | 4.68% | 30.01% | 45.91% | 86.21% | 31.37% |
| EBIT | 19.33% | 35.81% | 51.47% | 74.63% | 6.42% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 67.57% | 76.17% | 80.24% | 95.10% | 80.09% |
| Normalized Basic EPS | 67.69% | 76.23% | 80.29% | 95.13% | 80.05% |
| EPS Diluted | 67.57% | 76.17% | 80.24% | 95.10% | 80.09% |
| Normalized Diluted EPS | 67.69% | 76.23% | 80.29% | 95.13% | 80.05% |
| Average Basic Shares Outstanding | 195.31% | 193.67% | 173.57% | 181.61% | 244.34% |
| Average Diluted Shares Outstanding | 195.31% | 193.67% | 173.57% | 181.61% | 244.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
